This study is the first to compare the clinical outcomes of combined treatment of HAIC plus lenvatinib with or without PD-1 inhibitors in advanced CCA patients, and has demonstrated the promising safety and efficacy of the combination of the three treatments. Here, PDCD1 is linked to cholangiocarcinoma.